Skip to content
OpenCapital
Get started

Viatris VTRS Celebrex ® — Net Sales

Other product segments

Brands
$2.33B+10.2%
Generics
$1.18B+4.5%
Lipitor
$462M+19.1%
Norvasc
$210M+21.9%
Lyrica ®
$120.6M+7.1%
EpiPen® Auto-Injectors
$101.1M+4.6%
Creon ®
$97.4M+18.2%
Viagra ®
$95M-3.6%
Zoloft ®
$72.6M+20.6%
Yupelri ®
$62.5M+7.2%
Effexor ®
$62M+4.6%
Xalabrands
$39.2M+5.7%
Dymista ®
$37.3M-12.9%
Xanax ®
$34.8M+7.7%

Similar metrics at other companies

AbbVie logo
ABBVVenclexta — Net revenues
$770M+15.8%
Incyte logo
INCYNet sales — Total revenues
$1.1B+19.8%
ANI Pharmaceuticals logo
ANIPBrands — Net Revenues
$12.33M-50.9%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
Bristol-Myers Squibb logo
BMYNet product sales — Total Revenues
$11.17B+2.6%
Bristol-Myers Squibb logo
BMYAbraxane — Total Revenues
$50M-52.4%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$18.49B+81.7%
Enterprise value$31.3B+29.5%
P/S1.3×+0.5×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%—
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity1×+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's celebrex ® — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's celebrex ® — net sales?
Viatris (VTRS) reported celebrex ® — net sales of $67.1M in Q1 2026.
How has Viatris's celebrex ® — net sales changed year-over-year?
Viatris's celebrex ® — net sales increased by 5.8% year-over-year, from $63.4M to $67.1M.
What is the long-term trend for Viatris's celebrex ® — net sales?
Over 4 years (2021 to 2025), Viatris's celebrex ® — net sales has grown at a -5.7% compound annual growth rate (CAGR), from $344.4M to $272.9M.
What does celebrex ® — net sales mean?
This metric represents the total revenue generated from the sale of the Celebrex brand, a non-steroidal anti-inflammatory drug (NSAID) product line. It reflects the market demand, pricing power, and competitive positioning of this specific pharmaceutical asset within the company's broader portfolio of established medicines. Changes in this figure indicate the product's lifecycle stage, including potential impacts from generic competition, patent expirations, or shifts in clinical prescribing patterns.